In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

During the past ten years, circulating tumour cells (CTCs) have received enormous attention
as new biomarkers and the subject of basic research. Although CTCs are already used in …

The epithelial–mesenchymal transition (EMT) is a developmental program that enables
stationary epithelial cells to gain the ability to migrate and invade as single cells. Tumor cells …

EMT and MET comprise the processes by which cells transit between epithelial and
mesenchymal states, and they play integral roles in both normal development and cancer …

Circulating tumor cells, a component of the “liquid biopsy”, hold great potential to transform
the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of …

The potential clinical utility of circulating tumor cells (CTCs) in the diagnosis and
management of cancer has drawn a lot of attention in the past 10 years. CTCs disseminate …

The importance of early cancer diagnosis and improved cancer therapy has been clear for
years and has initiated worldwide research towards new possibilities in the care strategy of …

Tumor relapse and metastasis are the primary causes of poor survival rates in patients with
advanced cancer despite successful resection or chemotherapeutic treatment. A primary …

Cellular heterogeneity represents one of the greatest challenges in cancer therapeutics. In
many malignancies, this heterogeneity is generated during tumor evolution through a …

The primary reason for high mortality rates among cancer patients is metastasis, where
tumor cells migrate through the bloodstream from the original site to other parts of the body …